SAN DIEGO, Aug. 16, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it will host a conference call at 8:30 a.m. ET on Wednesday, August 17, 2011, to discuss the top-line results from its pivotal Phase 3 efficacy study (801) of Zohydro™ (hydrocodone bitartrate) extended-release capsules. Zohydro is being evaluated for the treatment of moderate to severe chronic pain in patients requiring around the clock opioid therapy for an extended period of time. If approved, Zohydro would be the first extended-release hydrocodone treatment and the first hydrocodone product without acetaminophen. Acetaminophen is associated with increased risk of liver toxicity when used in high doses over time. Zogenix will announce the top-line results from the Phase 3 efficacy study in a press release distributed prior to the conference call.
